Mirnas as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms
Interpace Diagnostics Corporation
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application 61/414,778, filed Nov 17, 2010. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,150,999 | Mirnas as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms In force · High confidence | Interpace Diagnostics, LLC | In force | High confidence | ||
| US 11,118,231 | Mirnas as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms In force · High confidence | Interpace Diagnostics, LLC | In force | High confidence | ||
| Application 17/400,660 | Mirnas as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms Abandoned Abandoned Sep 27, 2024 | Interpace Diagnostics, LLC | Abandoned | Abandoned Sep 27, 2024 | ||
| Application 18/815,470 | Mirnas as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms Pending Not granted | Interpace Diagnostics, LLC | Pending | Not granted |
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by Interpace Diagnostics Corporation.
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.